Events & Presentations
Presentation
Highlighted Events
10:45 AM EDT
Upcoming Events
Past Events
| Date | Event Details | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
November 22, 2021 10:00 AM EST |
|||||||||||||||||
|
November 18, 2021 3:00 AM EST |
|||||||||||||||||
|
October 19, 2021 10:45 AM EDT |
|||||||||||||||||
|
October 11, 2021 8:00 AM EDT |
View Presentation 515.9 KB
|
||||||||||||||||
|
July 28, 2021 5:00 PM EDT |
|||||||||||||||||
|
June 11, 2021 8:00 AM EDT |
Management will host an investor conference call and webcast to provide a brief corporate update and discuss data from its ongoing Phase 2 clinical study evaluating rusfertide in polycythemia vera (PV), which was selected as an oral presentation at the European Hematology Association 2021 Annual Congress. The conference call will take place on Friday, June 11, 2021, at 8:00 a.m. EDT (14:00 CEST). The call will feature members of the Protagonist management team and Ronald Hoffman, M.D., Albert A. and Vera G. List Professor of Medicine, Hematology and Medical Oncology, and Director of the Myeloproliferative Disorders Research Program at Mount Sinai Hospital, and a lead investigator of the Phase 2 study. To access the live call, dial (877) 870-4263 (U.S./Canada) or (412) 317-0790 (international) five minutes prior to the call and ask to be joined to the Protagonist Therapeutics call. A live and archived webcast will be accessible in the Investors section of the Company’s website at www.protagonist-inc.com. |
||||||||||||||||
|
June 11, 2021 9:00 AM CEST |
Title: Rusfertide (PTG-300) Eliminates the Need for Therapeutic Phlebotomy in Both Low and High-Risk Polycythemia Vera (PV) Patients
Session: Novel therapies and targets in MPN Abstract Number: S200 Presenter: Marina Kremyanskaya, MD, PhD, Assistant Professor of Medicine, Hematology and Medical Oncology, at the Icahn School of Medicine at Mount Sinai |
||||||||||||||||
| June 1 - June 4, 2021 | |||||||||||||||||
|
May 27, 2021 10:00 AM PDT |
A list of stockholders entitled to vote at the Annual Shareholder Meeting will be available for examination for any purpose germane to the Annual Shareholder Meeting for ten days prior to the Annual Shareholder Meeting. You may email ir@ptgx-inc.com to coordinate arrangements to view the stockholder list.
|
||||||||||||||||
|
March 22, 2021 5:00 PM EDT |
|||||||||||||||||
|
March 10, 2021 4:30 PM EST |
|||||||||||||||||
|
March 9, 2021 7:00 AM EST |
|||||||||||||||||
|
February 24, 2021 10:40 AM EST |
View Presentation 2.7 MB
|
||||||||||||||||
|
January 11, 2021 2:00 PM EST |
JP Morgan Event Presentation 2.2 MB
|
||||||||||||||||
|
December 9, 2020 8:30 AM EST |
|||||||||||||||||
| December 5 - December 8, 2020 |
|
||||||||||||||||
| November 30 - December 3, 2020 | |||||||||||||||||
|
November 17, 2020 12:35 PM EST |
View Presentation 2.7 MB
|
||||||||||||||||
|
September 23, 2020 8:00 AM EDT |
View Presentation 2.7 MB
|
||||||||||||||||
|
September 14, 2020 11:00 AM EDT |
|||||||||||||||||
|
September 11, 2020 12:00 PM EDT |
View Presentation 1.9 MB
|
||||||||||||||||
|
June 23, 2020 1:00 PM EDT |
|||||||||||||||||
|
June 18, 2020 1:40 PM EDT |
|||||||||||||||||
|
June 3, 2020 10:30 AM EDT |
|||||||||||||||||
|
May 28, 2020 10:00 AM PDT |
A list of stockholders entitled to vote at the Annual Shareholder Meeting will be available for examination for any purpose germane to the Annual Shareholder Meeting for ten days prior to the Annual Shareholder Meeting. You may email protagonist@troutgroup.com to coordinate arrangements to view the stockholder list.
|
||||||||||||||||
|
May 7, 2020 5:00 PM EDT |
|||||||||||||||||
|
March 10, 2020 4:30 PM EDT |
|||||||||||||||||
|
February 25, 2020 10:30 AM EST |
|||||||||||||||||
|
December 5, 2019 1:30 PM EST |
|||||||||||||||||
|
December 3, 2019 8:30 AM EST |
|||||||||||||||||
|
November 20, 2019 2:25 PM EST |
|||||||||||||||||
|
October 2, 2019 2:25 PM EDT |
|||||||||||||||||
|
September 10, 2019 9:10 AM EDT |
|||||||||||||||||
|
June 25, 2019 3:40 PM EDT |
|||||||||||||||||
|
June 7, 2019 10:00 AM PDT |
Directions 255.9 KB
101 California Street,
Fifth Floor, San Francisco, CA 94010 |
||||||||||||||||
| May 18 - May 21, 2019 |
DDW Presentation 466.5 KB
Title: The Oral α4β7 Integrin Specific Antagonist PN-10943 is More Effective Than PTG 100 in Multiple Preclinical Studies
Presenting Author: Larry Mattheakis, PhD, Sr. VP, Discovery Biology and Translational Research |
||||||||||||||||
|
May 8, 2019 8:30 AM EDT |
|||||||||||||||||
| April 9, 2019 |
9:50 a.m. BST
|
||||||||||||||||
|
March 12, 2019 4:30 PM EDT |
|||||||||||||||||
|
February 28, 2019 9:00 AM EST |
|||||||||||||||||
|
December 12, 2018 9:20 AM EST |
|||||||||||||||||
|
November 27, 2018 4:30 PM EST |
|||||||||||||||||
|
October 20, 2018 12:00 PM EDT through October 24, 2018 11:59 PM EDT |
Presentation Title: PTG-100, an oral gut-restricted peptide alpha-4-beta-7 antagonist induces clinical and histologic remission in patients with moderate to severely active ulcerative colitis |
||||||||||||||||
|
September 24, 2018 7:00 AM EDT |
Event date, time and location: October 1, 2018 at 4:40 PM EDT at the InterContinental New York Barclay Hotel
|
||||||||||||||||
|
August 6, 2018 8:00 AM EDT |
|||||||||||||||||
|
June 20, 2018 2:00 PM EDT |
|||||||||||||||||
|
June 14, 2018 12:00 PM CEST through June 17, 2018 11:59 PM CEST |
Presentation Title: Hepcidin mimetic PTG-300 for treatment of ineffective erythropoiesis and chronic anemia in hemoglobinopathy diseases
Date and Time: Saturday, June 16 from 11:45 AM to 12:00 PM CEST Session: Thalassemias Location: Stockholm International Fairs Convention Center, Room K2 Presentation Title: Hepcidin Mimetic PTG-300 induces dose-related and sustained reductions in serum iron and transferrin saturation in healthy subjects Date and Time: Saturday, June 16 from 5:00 PM to 5:15 PM CEST Session: Iron metabolism, deficiency and overload Location: Stockholm International Fairs Convention Center, Room A13 Stockholm, Sweden
Stockholm International Fairs |
||||||||||||||||
|
June 2, 2018 12:00 PM EDT |
Presentation Title: Oral delivery of peptides with dual mu/delta opioid receptor agonist activities are superior to eluxadoline in preclinical models of IBS-D
Date and Time: Saturday, June 2 from 5:00 PM to 5:15 PM ET Session: Diarrhea and Irritable Bowel Syndrome - New Advances Location: Washington Convention Center, Room 140 Presenting author: Larry Mattheakis, Vice President of Biology, Protagonist Therapeutics, Inc. Walter E. Washington Convention Center in Washington, D.C.
United States |
||||||||||||||||
|
May 29, 2018 11:00 AM PDT |
Conference Center
Pacific Research Center 7677 Gateway Blvd. Newark, California 94560 |
||||||||||||||||
|
March 26, 2018 8:00 AM EDT |
|||||||||||||||||
|
March 21, 2018 3:20 PM EDT |
The Westin New York Grand Central hotel in New York, NY
United States |
||||||||||||||||
|
March 15, 2018 11:15 AM EDT |
|||||||||||||||||
|
March 7, 2018 4:30 PM EST |
|||||||||||||||||
| February 26 - March 2, 2018 |
Location: Snowbird, UT |
||||||||||||||||
|
February 14, 2018 9:30 AM EST |
Lotte New York Palace in New York, NY
United States |
||||||||||||||||
|
December 14, 2017 8:00 AM EST |
Westin Grand Central Hotel, New York, NY
United States |
||||||||||||||||
|
November 15, 2017 10:15 AM EST |
Lotte New York Palace Hotel in New York, NY
United States |
||||||||||||||||
|
September 26, 2017 8:35 AM EDT |
InterContinental New York Barclay Hotel
New York, NY |
||||||||||||||||
|
May 30, 2017 8:00 AM EDT |
Event date and time: May 30, 2017 at 8:00 AM EDT
Webcast link: http://edge.media-server.com/m/p/bbh32fun Teleconference details: toll-free 844-515-9178 or toll call +1-614-999-9313, conference ID number 30341699 |
||||||||||||||||
|
May 25, 2017 10:00 AM PDT |
Protagonist - 2017 Proxy Statement 330.9 KB
Conference Center
Pacific Research Center 7677 Gateway Blvd. Newark, CA 94560 |
||||||||||||||||
|
May 6, 2017 12:00 PM EDT through May 9, 2017 11:59 PM EDT |
Presentation Title: The Biomarker Profile of PTG-200, an Oral Peptide Antagonist of IL-23 Receptor, Tracks with Efficacy in a Preclinical Model of IBD
Date and Time: Saturday, May 6 from 11:15 AM to 11:30 AM CT Location: McCormick Place, Room S102d Chicago, Illinois
United States |
||||||||||||||||
|
April 24, 2017 12:00 PM EDT through April 25, 2017 11:59 PM EDT |
Session: Advances in Peptide Therapeutics
Presentation: Discovery & Development of PTG-100, an Oral Peptide Antagonist of α4β7 Integrin, in Clinical Development for the Treatment of Inflammatory Bowel Disease Presenter: Ashok Bandari, Ph.D., Vice President, Chemistry, Protagonist Therapeutics Date and Time: 9-9:30 AM BST, Tuesday April 25 Room: Conference Room 3- Epernay London, UK, Novotel London West
United States |
||||||||||||||||
|
April 23, 2017 12:00 PM EDT through April 27, 2017 11:59 PM EDT |
Presentation: Biomarker Discovery and Development of PTG-200, an Oral Peptide Antagonist of IL-23 Receptor San Diego, CA, Sheraton San Diego Hotel and Marina
United States |
||||||||||||||||
|
March 21, 2017 2:10 PM EDT |
Westin New York Grand Central hotel, New York, NY.
United States |
||||||||||||||||
|
March 14, 2017 2:05 PM EDT |
Presenting: Dinesh V. Patel, Ph.D., Protagonist President and Chief Executive Officer
Miami, FL, Loews Miami Beach Hotel
United States |
||||||||||||||||
|
February 16, 2017 11:00 AM EST |
Presenting: Dinesh V. Patel, Ph.D., Protagonist President and Chief Executive Officer
New York, NY, Lotte New York Palace
United States |
||||||||||||||||
|
February 15, 2017 12:00 PM EST through February 18, 2017 11:59 PM EST |
Barcelona, Spain
United States |
||||||||||||||||
|
December 14, 2016 2:20 PM EST |
New York, NY |
||||||||||||||||
|
December 8, 2016 12:00 PM EST through December 9, 2016 11:59 PM EST |
Orlando, FL |
||||||||||||||||
|
November 7, 2016 12:00 PM EST through November 9, 2016 11:59 PM EST |
Cologne Germany
United States |
||||||||||||||||
|
October 15, 2016 12:00 PM EDT through October 19, 2016 11:59 PM EDT |
Vienna Austria
United States |
||||||||||||||||
|
August 23, 2016 10:00 AM EDT |
Philadelphia, PA
United States |